S&P 500   4,076.57 (-0.09%)
DOW   34,395.01 (-0.56%)
QQQ   293.41 (+0.02%)
AAPL   148.23 (+0.14%)
MSFT   254.49 (-0.25%)
META   120.45 (+1.99%)
GOOGL   100.94 (-0.05%)
AMZN   95.35 (-1.23%)
TSLA   194.67 (-0.02%)
NVDA   171.35 (+1.25%)
NIO   12.08 (-5.48%)
BABA   85.93 (-1.86%)
AMD   77.45 (-0.23%)
T   19.16 (-0.62%)
MU   55.39 (-3.92%)
CGC   3.93 (+8.56%)
F   14.08 (+1.29%)
GE   85.28 (-0.80%)
DIS   98.70 (+0.85%)
AMC   8.16 (+12.86%)
PYPL   78.51 (+0.13%)
PFE   51.15 (+2.03%)
NFLX   316.88 (+3.71%)
S&P 500   4,076.57 (-0.09%)
DOW   34,395.01 (-0.56%)
QQQ   293.41 (+0.02%)
AAPL   148.23 (+0.14%)
MSFT   254.49 (-0.25%)
META   120.45 (+1.99%)
GOOGL   100.94 (-0.05%)
AMZN   95.35 (-1.23%)
TSLA   194.67 (-0.02%)
NVDA   171.35 (+1.25%)
NIO   12.08 (-5.48%)
BABA   85.93 (-1.86%)
AMD   77.45 (-0.23%)
T   19.16 (-0.62%)
MU   55.39 (-3.92%)
CGC   3.93 (+8.56%)
F   14.08 (+1.29%)
GE   85.28 (-0.80%)
DIS   98.70 (+0.85%)
AMC   8.16 (+12.86%)
PYPL   78.51 (+0.13%)
PFE   51.15 (+2.03%)
NFLX   316.88 (+3.71%)
S&P 500   4,076.57 (-0.09%)
DOW   34,395.01 (-0.56%)
QQQ   293.41 (+0.02%)
AAPL   148.23 (+0.14%)
MSFT   254.49 (-0.25%)
META   120.45 (+1.99%)
GOOGL   100.94 (-0.05%)
AMZN   95.35 (-1.23%)
TSLA   194.67 (-0.02%)
NVDA   171.35 (+1.25%)
NIO   12.08 (-5.48%)
BABA   85.93 (-1.86%)
AMD   77.45 (-0.23%)
T   19.16 (-0.62%)
MU   55.39 (-3.92%)
CGC   3.93 (+8.56%)
F   14.08 (+1.29%)
GE   85.28 (-0.80%)
DIS   98.70 (+0.85%)
AMC   8.16 (+12.86%)
PYPL   78.51 (+0.13%)
PFE   51.15 (+2.03%)
NFLX   316.88 (+3.71%)
S&P 500   4,076.57 (-0.09%)
DOW   34,395.01 (-0.56%)
QQQ   293.41 (+0.02%)
AAPL   148.23 (+0.14%)
MSFT   254.49 (-0.25%)
META   120.45 (+1.99%)
GOOGL   100.94 (-0.05%)
AMZN   95.35 (-1.23%)
TSLA   194.67 (-0.02%)
NVDA   171.35 (+1.25%)
NIO   12.08 (-5.48%)
BABA   85.93 (-1.86%)
AMD   77.45 (-0.23%)
T   19.16 (-0.62%)
MU   55.39 (-3.92%)
CGC   3.93 (+8.56%)
F   14.08 (+1.29%)
GE   85.28 (-0.80%)
DIS   98.70 (+0.85%)
AMC   8.16 (+12.86%)
PYPL   78.51 (+0.13%)
PFE   51.15 (+2.03%)
NFLX   316.88 (+3.71%)
NASDAQ:BLFS

BioLife Solutions - BLFS Stock Forecast, Price & News

$21.87
+0.70 (+3.31%)
(As of 12/1/2022 03:59 PM ET)
Add
Compare
Today's Range
$21.15
$22.30
50-Day Range
$17.30
$25.07
52-Week Range
$10.40
$41.75
Volume
11,854 shs
Average Volume
460,407 shs
Market Capitalization
$935.38 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$31.20

BioLife Solutions MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
41.0% Upside
$31.20 Price Target
Short Interest
Bearish
7.66% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
-0.58mentions of BioLife Solutions in the last 14 days
Based on 11 Articles This Week
Insider Trading
Selling Shares
$2.18 M Sold Last Quarter
Proj. Earnings Growth
Growing
From ($0.63) to ($0.37) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.91 out of 5 stars

Medical Sector

774th out of 1,047 stocks

Electromedical Equipment Industry

15th out of 23 stocks

BLFS stock logo

About BioLife Solutions (NASDAQ:BLFS) Stock

BioLife Solutions, Inc. develops, manufactures, and supplies bioproduction tools and services for the cell and gene therapy industry in the United States, Canada, Europe, the Middle East, Africa, and internationally. The company's products are used in the basic and applied research, and commercial manufacturing of biologic-based therapies. It offers proprietary biopreservation media products, including HypoThermosol FRS and CryoStor that are formulated to mitigate preservation-induced, delayed-onset cell damage and death; and the ThawSTAR line that includes automated vial and cryobag thawing products that control the heat and timing of the thawing process of biologic materials. The company also provides evo shipping containers that are cloud-connected passive storage and transport containers for temperature-sensitive biologics and pharmaceuticals; liquid nitrogen laboratory freezers, cryogenic equipment, and accessories; and biological and pharmaceutical storage services. It markets and sells its products directly, as well as through third party distributors. BioLife Solutions, Inc. was incorporated in 1987 and is headquartered in Bothell, Washington.

Receive BLFS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for BioLife Solutions and its competitors with MarketBeat's FREE daily newsletter.

BLFS Stock News Headlines

BioLife Solutions (NASDAQ:BLFS) Trading Down 2.3%
StockNews.com Upgrades BioLife Solutions (NASDAQ:BLFS) to Sell
BioLife Solutions Expands Intellectual Property Estate
Earnings Outlook For BioLife Solutions
BioLife Solutions Inc
BioLife Solutions Inc. News
BioLife Solutions, Inc. (BLFS)
See More Headlines
Receive BLFS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for BioLife Solutions and its competitors with MarketBeat's FREE daily newsletter.

BLFS Company Calendar

Last Earnings
11/11/2021
Today
12/01/2022
Fiscal Year End
12/31/2022
Next Earnings (Estimated)
2/27/2023

Industry, Sector and Symbol

Industry
Electromedical equipment
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:BLFS
Employees
432
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$31.20
High Stock Price Forecast
$34.00
Low Stock Price Forecast
$29.00
Forecasted Upside/Downside
+42.7%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
1 Analysts

Profitability

Net Income
$-7,640,000.00
Pretax Margin
-72.07%

Debt

Sales & Book Value

Annual Sales
$119.16 million
Book Value
$9.55 per share

Miscellaneous

Free Float
41,355,000
Market Cap
$935.38 million
Optionable
Not Optionable
Beta
1.78

Key Executives

  • Mr. Michael P. RiceMr. Michael P. Rice (Age 59)
    Chairman & CEO
    Comp: $1.24M
  • Mr. Roderick de Greef (Age 62)
    Pres & COO
    Comp: $635.99k
  • Mr. Troy  WichtermanMr. Troy Wichterman (Age 37)
    Chief Financial Officer
    Comp: $290.72k
  • Dr. Aby J. MathewDr. Aby J. Mathew (Age 50)
    Chairman of Scientific Advisory Board, Exec. VP & Chief Scientific Officer
    Comp: $638.79k
  • Mr. Marcus  SchulzMr. Marcus Schulz (Age 43)
    Chief Revenue Officer
    Comp: $778.22k
  • Mr. Todd  BerardMr. Todd Berard (Age 53)
    Chief Marketing Officer
  • Ms. Sarah  Aebersold J.D.Ms. Sarah Aebersold J.D. (Age 46)
    VP of Global HR
  • Ms. Karen  FosterMs. Karen Foster (Age 62)
    Chief Quality Officer













BLFS Stock - Frequently Asked Questions

Should I buy or sell BioLife Solutions stock right now?

1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for BioLife Solutions in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" BLFS shares.
View BLFS analyst ratings
or view top-rated stocks.

What is BioLife Solutions' stock price forecast for 2023?

1 brokers have issued 12-month price targets for BioLife Solutions' stock. Their BLFS share price forecasts range from $29.00 to $34.00. On average, they anticipate the company's stock price to reach $31.20 in the next twelve months. This suggests a possible upside of 41.7% from the stock's current price.
View analysts price targets for BLFS
or view top-rated stocks among Wall Street analysts.

How have BLFS shares performed in 2022?

BioLife Solutions' stock was trading at $37.27 at the beginning of 2022. Since then, BLFS stock has decreased by 40.9% and is now trading at $22.02.
View the best growth stocks for 2022 here
.

Are investors shorting BioLife Solutions?

BioLife Solutions saw a increase in short interest in the month of November. As of November 15th, there was short interest totaling 3,030,000 shares, an increase of 16.1% from the October 31st total of 2,610,000 shares. Based on an average trading volume of 355,800 shares, the short-interest ratio is currently 8.5 days. Approximately 7.7% of the company's shares are short sold.
View BioLife Solutions' Short Interest
.

When is BioLife Solutions' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, February 27th 2023.
View our BLFS earnings forecast
.

How were BioLife Solutions' earnings last quarter?

BioLife Solutions, Inc. (NASDAQ:BLFS) announced its quarterly earnings results on Thursday, November, 11th. The medical equipment provider reported ($0.19) earnings per share (EPS) for the quarter, missing the consensus estimate of $0.02 by $0.21. The medical equipment provider earned $33.80 million during the quarter, compared to analyst estimates of $31.65 million. BioLife Solutions had a negative net margin of 67.70% and a negative trailing twelve-month return on equity of 7.50%. During the same quarter last year, the firm earned ($0.02) EPS.

What guidance has BioLife Solutions issued on next quarter's earnings?

BioLife Solutions updated its FY 2022 earnings guidance on Wednesday, November, 9th. The company provided EPS guidance of for the period. The company issued revenue guidance of $160.00 million-$164.00 million, compared to the consensus revenue estimate of $163.40 million.

What is Mike Rice's approval rating as BioLife Solutions' CEO?

14 employees have rated BioLife Solutions Chief Executive Officer Mike Rice on Glassdoor.com. Mike Rice has an approval rating of 100% among the company's employees. This puts Mike Rice in the top 10% of approval ratings compared to other CEOs of publicly-traded companies. 89.0% of employees surveyed would recommend working at BioLife Solutions to a friend.

What other stocks do shareholders of BioLife Solutions own?

Based on aggregate information from My MarketBeat watchlists, some companies that other BioLife Solutions investors own include Micron Technology (MU), AbbVie (ABBV), Cara Therapeutics (CARA), Gilead Sciences (GILD), Pfizer (PFE), Rigel Pharmaceuticals (RIGL), Sorrento Therapeutics (SRNE), Twilio (TWLO) and Verastem (VSTM).

What is BioLife Solutions' stock symbol?

BioLife Solutions trades on the NASDAQ under the ticker symbol "BLFS."

Who are BioLife Solutions' major shareholders?

BioLife Solutions' stock is owned by a number of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (12.66%), Vanguard Group Inc. (5.65%), Fred Alger Management LLC (5.06%), Geneva Capital Management LLC (3.61%), State Street Corp (2.88%) and Palisade Capital Management LLC NJ (2.16%). Insiders that own company stock include Aby J Mathew, Aby J Mathew, Amy Duross, Andrew G Hinson, Andrew G Hinson, Casdin Partners Master Fund, L, Greef Roderick De, James Mathers, Joseph C Schick, Karen A Foster, Karen A Foster, Marcus Schulz, Michael Rice, Of The University Of C Regents, Raymond W Cohen, Sarah Aebersold, Thomas Girschweiler, Todd Berard, Troy Wichterman and Walter Villiger.
View institutional ownership trends
.

How do I buy shares of BioLife Solutions?

Shares of BLFS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is BioLife Solutions' stock price today?

One share of BLFS stock can currently be purchased for approximately $22.02.

How much money does BioLife Solutions make?

BioLife Solutions (NASDAQ:BLFS) has a market capitalization of $941.80 million and generates $119.16 million in revenue each year. The medical equipment provider earns $-7,640,000.00 in net income (profit) each year or ($2.48) on an earnings per share basis.

How many employees does BioLife Solutions have?

The company employs 432 workers across the globe.

How can I contact BioLife Solutions?

BioLife Solutions' mailing address is 3303 MONTE VILLA PARKWAY SUITE 310, BOTHELL WA, 98021. The official website for the company is www.biolifesolutions.com. The medical equipment provider can be reached via phone at (425) 402-1400, via email at rdegreef@biolifesolutions.com, or via fax at 425-402-1433.

This page (NASDAQ:BLFS) was last updated on 12/1/2022 by MarketBeat.com Staff